Page 100 - Read Online

Page 6 of 7 Li et al. Hepatoma Res 2020;6:39 I http://dx.doi.org/10.20517/2394-5079.2020.13

treatment of liver cancer. In a word, it is safe and feasible to combine preoperative and postoperative
radiotherapy in the era of multidisciplinary comprehensive treatment, and it has also improved the curative
effect. However, more in-depth research is needed to further determine whether it can make HCC patients
benefit more from it.

DECLARATIONS

Authors’ contributions
Data analysis and interpretation and paper writing: Li JX
Conception and design of the study: Wu H, Zeng Y

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, et al. Tumor response to radiotherapy regulated by endothelial cell
apoptosis. Science 2003;300:1155-9.
2. Kolesnick R, Fuks Z. Radiation and ceramide-induced apoptosis. Oncogene 2003;22:5897-906.
3. Park HJ, Griffin RJ, Hui S, Levitt SH, Song CW. Radiation-induced vascular damage in tumors: implications of vascular damage in
ablative hypofractionated radiotherapy (SBRT and SRS). Radiat Res 2012;177:311-27.
4. Würthwein G, Klingebiel T, Krümpelmann S, Metz M, Schwenker K, et al. Population pharmacokinetics of high-dose etoposide in
children receiving different conditioning regimens. Anticancer Drugs 2002;13:101-10.
5. Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells:
changing strategies for cancer treatment. Blood 2009;114:589-95.
6. Cárdenes HR, Price TR, Perkins SM, Maluccio M, Kwo P, et al. Phase I feasibility trial of stereotactic body radiation therapy for primary
hepatocellular carcinoma. Clin Transl Oncol 2010;12:218-25.
7. Yoon SM, Lim YS, Park MJ, Kim SY, Cho B, et al. Stereotactic body radiation therapy as an alternative treatment for small hepatocellular
carcinoma. PLoS One 2013;8:e79854.
8. Kwon JH, Bae SH, Kim JY, Choi BO, Jang HS, et al. Long-term effect of stereotactic body radiation therapy for primary hepatocellular
carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer 2010;10:475.
9. Kimura T, Aikata H, Takahashi S, Takahashi I, Nishibuchi I, et al. Stereotactic body radiotherapy for patients with small hepatocellular
carcinoma ineligible for resection or ablation therapies. Hepatol Res 2015;45:378-86.
10. Scorsetti M, Comito T, Cozzi L, Clerici E, Tozzi A, et al. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-
institutional experience on stereotactic body radiation therapy (SBRT). J Cancer Res Clin Oncol 2015;141:1301-9.
11. Sanuki N, Takeda A, Oku Y, Mizuno T, Aoki Y, et al. Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective
outcome analysis in 185 patients. Acta Oncol 2014;53:399-404.
12. Andolino DL, Johnson CS, Maluccio M, Kwo P, Tector AJ, et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int
J Radiat Oncol Biol Phys 2011;81:e447-53.
13. Takeda A, Sanuki N, Eriguchi T, Kobayashi T, Iwabutchi S, et al. Stereotactic ablative body radiotherapy for previously untreated solitary